RecruitMe Clinical Trial

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in children 6 to less than 12 years of age with uncontrolled asthma
A study to evaluate dupilumab in children with uncontrolled asthma
Sponsor:Sanofi US & Regeneron Pharmaceuticals Inc.
Enrolling:Male and Female Patients
Age Range:Between 6 and 11 years old
IRB Number:AAAR0975
U.S. Government ID:NCT02948959
Contact: Elizabeth Duverger: 929-280-5799 / ed2714@cumc.columbia.edu
Additional Study Information:

This study is designed to examine the efficacy and safety profile of dupilumab over one year in a population of asthmatic children in need for an additional treatment to their current maintenance management. Patients are randomized to either dupilumab or matching placebo administered standard care for a maximum treatment duration of 52 weeks. The investigator hopes to better understand the efficacy of dupilumab on multiple asthma domains including prevention of severe exacerbation, lung function, and symptom control. The short and long term effects on lung function and symptom control will be evaluated.

Do You Qualify?
Is your child between age 6 and 11?YesNo
Does your child have evidence of uncontrolled asthma?YesNo
Does your child weigh less than 16 kg?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Elizabeth Duverger
Email: ed2714@cumc.columbia.edu
Phone: 929-280-5799